Compare Crispr Therapeutics AG (CRSP) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Xylem, Inc. — how do they compare? Crispr Therapeutics AG trades at $51.36 (market cap $4.97B), while Xylem, Inc. trades at $121.6 (market cap $28.89B). The key difference: Xylem, Inc. is far larger — about 5.8× Crispr Therapeutics AG's market cap, and Xylem, Inc. pays a 1.42% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | XYL | |
|---|---|---|
Market Cap | $4.97B | $28.89B |
Sector | Health | Industrials |
52-Week High | $76.78 | $152.95 |
52-Week Low | $44.34 | $106.34 |
Enterprise Value | $3.32B | $30.14B |
Dividend Yield | — | 1.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
XYL trades at $121.21, showing minimal daily change. The stock maintains a bullish technical outlook with consistent earnings beats in recent quarters. Revenue grew to $9.04B in 2025 with a net margin of 10.79%. Recent news highlights strategic partnerships and leadership appointments, reinforcing growth in water technology solutions. Analyst consensus is mixed with a $153.14 price target suggesting 26% upside from current levels.
XYL offers solid fundamentals with expanding profitability and strong cash flow generation. Key risks include execution of growth initiatives and macroeconomic sensitivity. The stock presents a compelling opportunity for long-term investors seeking exposure to essential water infrastructure, though near-term volatility may persist around earnings announcements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
